Bradley L. Campbell
President and Chief Executive Officer, Travere Therapeutics, Inc. · United States
Bradley L. Campbell is the CEO of Travere Therapeutics, Inc. (TVTX). Campbell is based in the United States.
Bradley L. Campbell is a veteran biopharmaceutical executive with over 25 years of industry experience. He previously served as President and Chief Executive Officer of Amicus Therapeutics from 2022 until its acquisition by BioMarin in April 2026, having held roles of increasing responsibility at Amicus since 2006. He has held commercial and business development roles at Genzyme Corporation and Bristol-Myers Squibb.
Recent developments
AI summary of recent coverageRecent coverage has focused on Bradley Campbell's appointment as chief executive officer of Travere Therapeutics, effective December 1, 2026, following the planned departure of the incumbent CEO. The leadership transition announcement coincided with a decline in the company's stock price.
Summarized from the headlines below; see each source for the full story.
Our coverage
On CEOInsider
No feature yet. When we publish a feature, interview or cover story on Bradley L. Campbell, it will appear here — and tie into the news timeline.
Bradley L. Campbell: FAQ
- Who is Bradley L. Campbell?
- Bradley L. Campbell is the President and Chief Executive Officer of Travere Therapeutics, Inc., based in United States.
- What company does Bradley L. Campbell lead?
- Bradley L. Campbell is CEO of Travere Therapeutics, Inc..